Monoclonal Antibodies

End-to-end development and manufacturing capabilities across different therapeutic modalities and the entire product lifecycle

Cutting-edge technology platforms for high yielding cell lines (both mammalian and microbial) and high concentration formulations


Integrated and flexible drug sub...

Eurofins CDMO Alphora Inc. provides integrated solutions for small molecules, drug product, biologics and phytocannabinoids. Specializing in complex and niche small molecule drug substance and drug product services, including high potent capabilities, we provide support from preclinical to commercial devel...

HANBEITAI (generic name: bevacizumab), the fourth product independently developed by Henlius, received marketing approval from the National Medical Products Administration (NMPA) in November 2021, and its commercialization in Chinese mainland is handled by the company’s in-house team. As of now, HANBEI...

• Pegfilgrastim (Filed with EMA) • Filgrastim (Filed with EMA) • Trastuzumab (Filed with EMA, MHRA, Received recommendation for marketing authorization in India) • Bevacizumab (Filed with MHRA) • Omalizumab (Global PhIII ongoing) • Denosumab (Global PhIII ongoing) • Ranibizumab (Global PhIII ongoing...

This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.

Built on the SUREtechnology Platform, SUREmAb optimizes monoclonal antibody (mAb) development and manufacturing processes, fast-tracking the path to clinic and market. • Fast-tracked for efficiency and speed, taking you from DNA transfection to GMP drug substance in 11 months • Comprehensive mAb develop...

Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ...

UV Light Blocking Tyvek Equipment Covers are designed to keep cleaned pharmaceutical equipment and supplies clean and protected from external sources of contamination while also providing in-process protection to light sensitive biotech products.

UDP-Gal is a nucleotide sugar consisting of the nucleotide uridine 5'-diphosphate and a phosphate-bound monosaccharide, α-D-galactose. Nucleotide sugars are the activated forms of monosaccharides required for cellular metabolism and biosynthesis reactions. UDP-gal serves as a donor substrate for galactosyl...

From pre-clinical development to commercial supply, Patheon by Thermo Fisher Scientific is an industry leader in the development and manufacture of mammalian cell culture drug substances. Patheon offers biotech and pharmaceutical companies the ability to pursue opportunities around the globe with a fully i...

Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, murine monoclonal antibodies may induce immunogenic responses, potentially limiting their application for humans. Humanized antibodies can overcome these problems and are considered to be a ...

Zamerovimab and Mazorelvimab Injection (SYN023) is the World’s First Humanized mAb Cocktail against Rabies. It has approved in China since 2024. 

GMP manufacturing of Monoclonal Antibodies for early-phase through all clinical stages

Also serving the Diagnostic industry with high quality antibodies

Exporting antibodies worldwide, including the US

Fundamental to your biopharmaceutical chemistry, manufacturing and controls (CMC) development, you will need detailed analytical characterisation data to satisfy regulatory requirements. Our experts strategically deploy orthogonal protein analysis approaches that address key molecular and biological charac...

HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) was successfully launched in the U.S., China and Europe, becoming the Chinese mAb biosimilar entering the U.S., the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic bre...

Our first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, uveitis, polyarticular juvenile idiopathic arthritis,  pediatric plaque ...

HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and Indonesia. Up to date, 4 indications are approved for marketing, 2 marketing applications a...

HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has bee...

Rituximab binds itself to the CD20 protein, marking them, and subsequently triggering the cells of the immune system to pick out the marked cells and kill them.The indication is for Non Hodgkin Lymphoma

Trastuzumab binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. The indication is for HER2 Triple Positive and HER2+ Gastric Cancer / Gastroesophageal Junction cancer.